A genomic analysis study by Rutgers Cancer Institute of New Jersey investigators and others has identified recurrent genomic alterations in a subset of breast cancer that are typically associated with a form of thyroid cancer and an intestinal birth defect. Associate Director for Translational Science and Omar Boraie Chair in Genomic Science Shridar Ganesan, MD, PhD, and breast medical oncologist Kim M. Hirshfield, MD, PhD, who are both faculty members at Rutgers Robert Wood Johnson Medical School, were involved in the work that was presented at the recent San Antonio Breast Cancer Symposium.

Childhood cancer patients rely on clinical trials to find better, safer cures that can prevent lifelong damage as a result of radiation and chemotherapy. Rutgers Cancer Institute of New Jersey has been awarded an infrastructure grant from the St. Baldrick's Foundation to expand access to clinical trials. Funding from St. Baldrick's totaling $50,000 will ensure that additional adolescent and young adult patients can be treated by clinical trials with the most innovative drugs and therapies available at Rutgers Cancer Institute.